California institute outlines stem-cell strategy

The California Institute for Regenerative Medicine has laid out a strategic plan to systematically explore the basic science of stem cell research while pursuing new therapies for some of the world's harshest ailments. As a result, the stem cell institute is warning against unrealistic expectations about quick miracle cures for Alzheimer's and other diseases like macular degeneration. New therapies are likely to take 10 years to develop. Some patient advocates, though, is criticizing the institute for a go-slow approach. Right now, the institute is being funded by loans from the state and others as it fights lawsuits over the $3 billion bond program intended to spur new advances.

- here's the report on the institute from the San Jose Mercury New

Related Articles
California stem-cell institute open for business. Report
Wealthy supporters back California stem cell research. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.